FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)												
1. Name and Address Gormally John J	2. Issuer Name and Ticker or Trading Symbol Akers Biosciences, Inc. [AKER]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) 80 WALSH DRIV	(First) VE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/17/2017						X Officer (give title below) Other (specify below) Chief Executive Officer Other (specify below)			
MAHWAH, NJ 0'	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)		Date (Month/Day/Year)	Execution Date, if	Code (Instr. 8)		(A) or Disposed of (D)		of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form:	Beneficial Ownership	
Common Stock		10/17/2017		G		150,000 (1)	А	\$ 0.88	180,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information

SEC 1474 (9-02)

contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned nuts calls warrants ontions convertible se

(e.g., puts, caus, warrants, options, convertible securities)																			
1. Title of	2.	3. Transaction	3A. Deemed	4.		5.		6. Date Exer	cisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature				
Derivative	Conversion	Date	Execution Date, if	Transacti	on	Numl	ber	and Expirati	on Date	Amo	unt of	Derivative	Derivative	Ownership	of Indirect				
Security	or Exercise	(Month/Day/Year)	any	Code		of		(Month/Day/Year)		(Month/Day/Year)		(Month/Day/Year)		Unde	rlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Deriv	ative	· · · ·		Securities		(Instr. 5)	Beneficially	Derivative	Ownership				
	Derivative					Secur				(Instr	. 3 and		Owned	Security:	(Instr. 4)				
	Security					Acqu	ired			4)			Following	Direct (D)					
						(A) o							1	or Indirect					
						Dispo							Transaction(s)	< / </td <td></td>					
						of (D	· · · · · · · · · · · · · · · · · · ·						(Instr. 4)	(Instr. 4)					
						(Instr	· · ·												
						4, and	15)												
											Amount								
								D.	.		or								
									Expiration	Title	Number								
								Exercisable	Date		of								
				Code	V	(A)	(D)				Shares								
				Code	v	(A)	(D)				Shares								

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Gormally John J 80 WALSH DRIVE MAHWAH, NJ 07430	Х		Chief Executive Officer					

Signatures

/s/ John J. Gormally	10/24/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 150,000 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.